我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
346
36 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
4
1.2%
已完成
101
29.2%
Enrolling By Invitation
5
1.4%
尚未招募
27
7.8%
招募中
57
16.5%
终止
3
0.9%
Unknown
147
42.5%
撤回
2
0.6%
暂无批准数据
- A 52-year-old woman with metastatic hepatocellular carcinoma showed circulating tumor cells with EGFR mutations (exon 19 deletion and L858R), leading to targeted therapy selection. - EGFR tyrosine kinase inhibitors including erlotinib, afatinib, and osimertinib achieved partial response in lung metastases with treatment benefit lasting 14 months. - The case demonstrates potential for CTC molecular profiling to guide personalized treatment in HCC, where traditional tissue biopsy is often limited by bleeding risk. - EGFR upregulation occurs in approximately 66% of HCC cases, but canonical sensitizing mutations are rare, making CTC analysis particularly valuable for treatment selection.
